A 38-year-old woman with asthma and seasonal allergies is prescribed albuterol (salbutamol) inhaler for acute bronchospasm. She uses it 3–4 times daily for 2 weeks and reports tremor in her hands, palpitations, and mild anxiety. Her heart rate is 102 bpm at rest, and she has a fine tremor on finger extension. Spirometry shows FEV₁ of 78% predicted (baseline 85%). What is the most appropriate next step in management?

Explanation

## Clinical Context This patient is experiencing β₂-adrenergic overstimulation adverse effects (tremor, tachycardia, anxiety) from frequent albuterol use. The pattern of frequent use (3–4 times daily) suggests inadequate baseline asthma control, not just acute bronchospasm. ## Mechanism of Adverse Effects **Key Point:** β₂-adrenergic agonists activate β₂ receptors on airway smooth muscle (desired bronchodilation) but also on skeletal muscle, heart, and metabolic tissues (unwanted effects). Tremor results from β₂ stimulation of skeletal muscle; tachycardia and anxiety from β₁ and β₂ stimulation in the heart and CNS. ## Receptor Selectivity and Side Effects | Agent | β₂ Selectivity | Tremor | Tachycardia | Duration | Use | |-------|---|---|---|---|---| | Albuterol (salbutamol) | Moderate | Common | Common | 4–6 hrs | Acute relief | | Terbutaline | Moderate | Common | Common | 4–6 hrs | Acute relief | | Salmeterol | High | Less | Less | 12 hrs | Maintenance (LABA) | | Formoterol | High | Less | Less | 12 hrs | Maintenance (LABA) | **High-Yield:** Frequent use of short-acting β₂ agonists (SABA) indicates poor baseline control and is a marker for stepping up to inhaled corticosteroid (ICS) therapy. GINA and NAEPP guidelines recommend ICS as the foundation of asthma management, with SABA reserved for true acute symptoms. ## Management Algorithm ```mermaid flowchart TD A[Frequent SABA use + β₂ adverse effects]:::outcome --> B{Asthma control adequate?}:::decision B -->|No - frequent use| C[Step up therapy]:::action B -->|Yes - occasional use| D[Continue SABA PRN]:::action C --> E[Add inhaled corticosteroid]:::action E --> F[Reduce SABA to PRN only]:::action F --> G[Reassess control in 2-4 weeks]:::outcome D --> H[Monitor and educate]:::action ``` ## Why This Answer 1. **Addresses root cause:** Frequent SABA use indicates poor baseline control, not inadequate dosing. 2. **Guideline-aligned:** ICS is the foundation of asthma therapy; SABA should be PRN only. 3. **Reduces adverse effects:** Lower SABA frequency automatically reduces tremor, tachycardia, and anxiety. 4. **Improves FEV₁:** ICS will improve baseline lung function (currently 78% predicted).